Meningitis B: your questions answered

The health secretary Wes Streeting has asked the Joint Committee on Vaccination and Immunisation (JCVI) to review its advice on the MenB vaccine, following an outbreak in Kent, which as of 1pm on Thursday 19 March has been linked to 27 confirmed and suspected cases of invasive meningococcal disease.

We asked Full Fact readers for their specific questions about the vaccine and the disease itself, and have started answering them below. We plan to continue adding more answers as we get to them.

You can find further information about the Meningitis B outbreak from the UK Health Security Agency on the Gov.uk website.

Babies are at the highest risk of invasive meningococcal disease (IMD) from the germ known as MenB, so since 2015 they have been offered the MenB vaccine on the NHS.

The government says this has been shown to be 83% effective at preventing all forms of the disease, and rates of MenB disease in young children have fallen since.

The NHS also offers the vaccine to some other people who are at higher risk, including those with coeliac disease, sickle cell anaemia, spleen disorders and complement disorders.

Shortly before the MenB vaccine was introduced, the JCVI considered whether it should also be routinely offered to adolescents, given that people in their late teens are the second highest risk group.

This was a complex question, but in the end the JCVI concluded that while vaccinating adolescents might be cost effective “the degree of uncertainty regarding duration of protection and protection against acquisition of meningococcal carriage meant the Committee was unable to form a recommendation on the use of [the vaccine] in adolescents, as there was a significant risk such a programme would result in a net loss of health in the population through displacement of other interventions within the health service”.

In short, there wasn’t convincing evidence that a vaccination programme in adolescents would do more good than harm overall.

In March 2025, the JCVI’s meningococcal subcommittee heard new evidence “which showed that MenB vaccination did not reduce carriage significantly in teenagers”. Minutes from the subsequent JCVI meeting said: “These results emphasised that MenB vaccines should be used primarily for providing direct protection to individuals.”

However, as we’ve noted, the health secretary has now asked the JCVI to review its advice on the MenB vaccine.

The meningococcal group B, or MenB, bacteria is common in the UK and usually stays in people’s throat or noses, where it rarely causes serious illness.

On occasion it can infect other parts of the body and become life-threatening. When this happens, it is called invasive meningococcal disease or IMD, and it most often affects either the blood (septicaemia) or the lining of the brain (meningitis) or both.

We don’t know which types of disease have been involved in the cases identified so far.

The daily updates from the UK Health Security Agency (UKHSA) list the number of cases of invasive meningococcal disease.

The terms are easy to mix up. In fact, while researching this article we noticed that a UKHSA blog confused the two. The agency has now corrected this after we got in touch.

The government is offering the MenB vaccine for free in a targeted campaign to about 5,000 people at the University of Kent, and this may be extended to more people as required.

It is not currently offered for free to most people, as the risk to the general population is low—although it can be taken privately where stocks are available.

As the UKHSA says, the MenB vaccine stops people getting ill from the disease, but it doesn’t stop them carrying or spreading it, which is why it is targeting people at ongoing increased risk of exposure.

The MenACWY vaccine, which protects against other forms of meningitis and septicaemia, is offered to all children when they are 13 or 14, or slightly older in Northern Ireland. Anyone who has missed this can catch up until the age of 25.

Scientists are still trying to understand exactly how long protection lasts, but it does seem that the vaccine only protects people for a few years—not for their whole life.

Speaking to the Science Media Centre, several scientists have given their opinion on this.

• Adam Finn, Professor Emeritus of Paediatrics at the University of Bristol, said: “Protection by the vaccine lasts for some years but not forever.”
• Johnjoe McFadden, Emeritus Professor at the University of Surrey, said: “The vaccine, given in two [doses], at least four weeks apart, offers up to three years of protection from the infection.”
• Dr Eliza Gil, Clinical Lecturer at the London School of Hygiene & Tropical Medicine, said: “The protection the vaccine offers is imperfect and is thought to only last a few years.”
• Dr David Elliman, Honorary Associate Professor in Child Health at UCL GOSH Institute of Child Health, said: “The protection from the vaccine appears not to last as long as that from the MenACWY vaccines.”

The MenB vaccine protects people against the disease, but not from carrying or spreading it. It is effective against many strains of MenB, but not all of them.

The vaccine protection is very good, but not perfect. Dr Bharat Pankhania, Senior Clinical Lecturer in Public Health Medicine at the University of Exeter Medical School, says that the vaccine offers about 70-90% protection against the most common forms of MenB meningococcal disease, and about 50-70% protection against the most invasive forms.

Got a question?

We’ll be adding to this article in the coming days. If you’ve seen something you’d like us to fact check or explain, please let us know on X or Facebook, or via our website. While we can’t respond to every message, we’ll use your suggestions to help shape the article as we add to it.